United Therapeutics: The Market Sees The Erosion, Not The Refill

United Therapeutics is rated Buy with a $535/share base-case valuation despite revenue pressure from Liquidia's competing Yutrepia product. The weakness is concentrated in older Tyvaso formulations, while the larger Tyvaso DPI franchise continues to grow. FDA reviews for IPF and Ralinepag, alongside potential label expansions and launches, represent meaningful upside catalysts.

Analysis

The investable question is whether competitive erosion remains confined to legacy inhaled formulations or migrates into Tyvaso DPI. If DPI prescription growth and persistence remain intact over the next two quarterly disclosures, the market is likely over-penalizing UTHR for a cannibalization event in a declining delivery format; this would support multiple expansion given UTHR's cash-generative profile and relatively concentrated but durable PAH franchise. Conversely, a deceleration in DPI net-product sales, rather than total Tyvaso sales alone, is the key falsifier because it would indicate that LQDA's commercial advantage is broader than formulation substitution.

LQDA has materially more asymmetric near-term exposure: incremental Yutrepia uptake can drive large percentage revenue revisions from a low base, but its valuation will increasingly depend on gross-to-net discounts, payer access, manufacturing execution, and the cost required to displace an incumbent. A faster-than-expected launch may therefore be negative for UTHR's legacy revenue without translating one-for-one into LQDA operating leverage. The second-order beneficiary of UTHR defending share could be its own earnings power: reducing promotional intensity after the launch period would preserve margins, while a prolonged price/access battle would compress both companies' economics.

Over 1-3 months, FDA timing around IPF and ralinepag is likely more important to UTHR's stock than modest quarterly legacy-Tyvaso variance, because either catalyst broadens the growth narrative beyond a single competitive dispute. Over 6-18 months, the risk is regulatory or clinical disappointment combined with continued Yutrepia conversion, which would turn a perceived portfolio-transition story into a terminal-value reset. The contrarian view is that consensus may be assigning too much value to pipeline optionality before approval and too little probability to payer-led substitution if Yutrepia achieves favorable formulary positioning.

Key Decisions for Investors

• Maintain or initiate a 6-12 month long UTHR position only if Tyvaso DPI growth remains positive on the next earnings report; target a rerating toward the stated $535 base case, with thesis invalidation if DPI growth turns negative or management cuts full-year Tyvaso/DPI guidance.
• Use a pair structure: long UTHR / short LQDA after sharp LQDA launch-driven rallies, sized modestly. The trade expresses that LQDA revenue upside may be real but that launch spending, rebates, and a valuation built on rapid share capture create downside if conversion data disappoint over the next 2-3 quarters.
• Do not add directional LQDA exposure ahead of verifying quarterly Yutrepia net sales, formulary wins, and gross-margin trajectory. An alert threshold is evidence that revenue growth is being purchased through materially rising sales-and-marketing expense or unfavorable gross-to-net adjustments.
• For UTHR event exposure, prefer defined-risk upside structures spanning the relevant FDA decision windows rather than treating approvals as base-case earnings. Reduce exposure if a regulatory delay occurs, since timing slippage would leave the stock more exposed to near-term Yutrepia share-loss headlines.